ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Uniqure Nv

Uniqure Nv (0EE0)

31.50
0.00
(0.00%)
Cerrado 29 Enero 10:30AM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
31.50
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
427
0.00 Rango del Día 0.00
31.50 Rango de 52 semanas 31.50
Capitalización de Mercado [m]
Precio Anterior
31.50
Precio de Apertura
-
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
12,613
Acciones en circulación
47,834,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.36
Beneficio por acción (BPA)
-6.45
turnover
21.9M
Beneficio neto
-308.48M

Acerca de Uniqure Nv

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Amsterdam, North Holland, Nld
Fundado
-
Uniqure Nv is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0EE0. The last closing price for Uniqure Nv was US$31.50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure Nv currently has 47,834,000 shares in issue. The market capitalisation of Uniqure Nv is US$1.51 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -2.36.

0EE0 Últimas noticias

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10031.531.531.5194031.5DE
40031.531.531.5263531.5DE
120031.531.531.51261331.5DE
260031.531.531.5812831.5DE
520031.531.531.5887031.5DE
1560031.531.531.5329531.5DE
2600031.531.531.5208231.5DE

0EE0 - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Uniqure Nv?
El precio actual de las acciones de Uniqure Nv es US$ 31.50
¿Cuántas acciones de Uniqure Nv están en circulación?
Uniqure Nv tiene 47,834,000 acciones en circulación
¿Cuál es la capitalización de mercado de Uniqure Nv?
La capitalización de mercado de Uniqure Nv es USD 1.51B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Uniqure Nv?
Uniqure Nv ha negociado en un rango de US$ 31.50 a US$ 31.50 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Uniqure Nv?
El ratio precio/beneficio de Uniqure Nv es -2.36
¿Cuál es el ratio de efectivo a ventas de Uniqure Nv?
El ratio de efectivo a ventas de Uniqure Nv es 33.24
¿Cuál es la moneda de reporte de Uniqure Nv?
Uniqure Nv presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Uniqure Nv?
El último ingresos anual de Uniqure Nv es USD 21.9M
¿Cuál es el último beneficio anual de Uniqure Nv?
El último beneficio anual de Uniqure Nv es USD -308.48M
¿Cuál es la dirección registrada de Uniqure Nv?
La dirección registrada de Uniqure Nv es PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP
¿Cuál es la dirección del sitio web de Uniqure Nv?
La dirección del sitio web de Uniqure Nv es www.uniqure.com
¿En qué sector industrial opera Uniqure Nv?
Uniqure Nv opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MACMarechale Capital Plc
3.80p
(117.14%)
38.62M
DKEDukemount Capital Plc
0.045p
(42.86%)
905.37M
SCGLSealand Capital Galaxy Limited
8.00p
(37.93%)
13.92M
OBDOxford Biodynamics Plc
0.65p
(30.00%)
5.03M
BKYBerkeley Energia Limited
19.25p
(20.31%)
1.06M
NFXNuformix Plc
0.085p
(-41.38%)
262.46M
PPSProton Motor Power Systems Plc
0.225p
(-25.00%)
983.97k
VASTVast Resources Plc
0.115p
(-19.30%)
183.07M
GSCGs Chain Plc
1.30p
(-16.13%)
629k
SYMESupply@me Capital Plc
0.0026p
(-16.13%)
144.24M
DKEDukemount Capital Plc
0.045p
(42.86%)
905.37M
NTVONativo Resources Plc
0.0019p
(0.00%)
467.88M
INSPInspirit Energy Holdings Plc
0.0029p
(11.54%)
429.63M
MSMNMosman Oil And Gas Limited
0.025p
(-3.85%)
401.42M
TRPTower Resources Plc
0.0285p
(-3.39%)
303.27M
Hummingbird2 Hummingbird2 5 minutos hace
https://x.com/GTIIReceiver/status/1884699111691346394


$FNGR
FNGR
Turbomunkey Turbomunkey 5 minutos hace
That's an interesting idea. We shall see.
PTLO
IronSeer69 IronSeer69 6 minutos hace
Sorry for my ignorance, but what does this mean?
zab zab 6 minutos hace
Thanks President Biden for solving the trump pandemic and restoring America. 
dukeb dukeb 6 minutos hace
Entirely possible. And why did they need an office, really? They aren't conducting any business. Mark and his amigos probably haven't set foot in the office in years. Given that they can't pay their auditors it seems unlikely that they have money to pay rent or utilities.

Wonder i
ZRFY
Turbomunkey Turbomunkey 7 minutos hace
Thanks Rio
NXPL
getmoreshares getmoreshares 7 minutos hace
slower today- dollar Volume $ 19,505
NBRI
don estaban don estaban 8 minutos hace
Hopefully were close to something soon !!!
MVNT
Hummingbird2 Hummingbird2 8 minutos hace
https://www.youtube.com/watch?v=7C9Ss-lrV-M

$GTII
GTII
gimmee greenbacks gimmee greenbacks 8 minutos hace
https://www.actipatchtw.com/general-1



BIEL
BIEL
getmoreshares getmoreshares 8 minutos hace
agree-- posting things that have already been disproven.
NBRI
nwsun nwsun 9 minutos hace
You make sense. Others obviously rely on hopeful innocence. Wall St, where sociopaths are trained.
ADTX
bradford86 bradford86 9 minutos hace
how you like ackman pres?
FNMA
dipANDrip dipANDrip 9 minutos hace
Buy 0001/0002 lotto and wait. That is all 
DPLS
Zorax Zorax 10 minutos hace
Hasn't looked like human careful structure for a while now. AI can't tell the difference of that nuance of a compound sentence.
Howzitgoing Howzitgoing 11 minutos hace
Have you noticed ...?

Have you noticed Breathe is a respiratory medicine company exclusively licensed to use JadiCells. Or epilepsy bio, exclusively licensed to use jadicells in epilepsy? or ALS Biologics exclusively licensed to use jadicells in ALS. Those companies, controlled by TS
TSOI
Wrangler1 Wrangler1 11 minutos hace
5% of zero is zero. The TBI's ain't generating any revenue to speak of after being in biz for years. 
WDLF
TheSprinx TheSprinx 12 minutos hace
Good read. From Reddit:
https://www.reddit.com/r/HMBLblockchain/s/MA76wt6hlo


HMBL
Bubae Bubae 12 minutos hace
I have been looked back at the restricted share activity. Fortunately we have a board member who has been diligent in posting the outstanding share count updates. I have only been looking at this sine the beginning of January and have found these posts useful. Raadr had a huge balance of restricted
RDAR
TenKay TenKay 13 minutos hace
Meant 3(a)10…well known mechanism to get stock free trading by deceiving a judge as to the parties true intentions.
MULN

Su Consulta Reciente

Delayed Upgrade Clock